ArticleClinical Medicine Insights. Oncology2014

Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment.

David Parker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.